Pinealon: research

A peptide with unproven brain benefits and no established injection dose.

Also called: EDR, Glu-Asp-Arg, glutamyl-aspartyl-arginine.

Khavinson bioregulator peptides · Synthetic tripeptide studied for nerve-cell protection.

14 human reports or summaries may reuse some participants. Independent trials have not confirmed a benefit.

Studies

• Head injury: patent example. rct, n=25, 25 adults aged 31–60 with remote head injury. A patent describes human IM exposure, with major reporting gaps. (source)
• Mixed brain disorders: internal report. cohort, n=74, Adults with head-injury effects, prior stroke, vascular brain disease or memory complaints. An internal oral-use report suggests symptom changes but cannot establish benefit or safety. (source)
• Head injury: review-described cohort. cohort, n=109, 72 adults aged 30–74 with head-injury effects and fatigue; 37 usual-care controls. A review reports oral human exposure but lacks usable comparative outcome numbers. (source)
• Older adults: emotional symptoms. cohort, Older adults with emotional symptoms; a later review describes 75 recipients. This report is part of the human record, but its detailed dosing remains unverified. (source)
• Locomotive workers: oral course. single-arm, n=146, 146 male locomotive workers, aged 20–50, in two age groups. Work and health scores changed after oral dosing; causation is uncertain. (source)
• Locomotive workers: companion report. single-arm, Locomotive crew workers. The abstract confirms a 100 mcg twice-daily oral schedule. (source)
• Truck drivers: peptide combinations. cohort, n=300, 150 male truck drivers and 150 metal workers. The report suggests symptom changes but does not isolate Pinealon. (source)
• Judo athletes: stepped oral course. single-arm, n=18, 18 female judo athletes aged 16–22. A small uncontrolled report used a step up, then down, over 15 days. (source)
• Gymnasts: Pinealon with Crystagen. rct, n=20, 20 elite rhythmic gymnasts. A very small combination study cannot show Pinealon alone improves recovery. (source)
• Workers: work-ability analysis. cohort, People in hazardous occupations. The work-ability paper adds limited, potentially repeated human evidence. (source)
• Chronic illness: 32-person report. cohort, n=32, Adults aged 41–83 with multiple illnesses and stable organic brain symptoms. This small report includes concerning marker changes as well as claimed benefit. (source)
• 110 adults: several aging interventions. cohort, n=110, 110 adults of differing ages. This comparison does not establish an effective dose or reliable safety rate. (source)
• Northern workers: personalized mixtures. cohort, n=113, 113 gas-industry workers given genotype-guided interventions. A multi-product workplace program cannot establish Pinealon effects. (source)
• Older men: four-group monograph report. rct, n=170, 170 men aged 60–74. A developer monograph describes randomized exposure without independent replication. (source)
• Human-derived neurons in a dish. in-vitro, Induced neurons made from older donor skin cells. Cell findings support a hypothesis, not a cognitive or sleep benefit. (source)
• Oxidative stress in cells. in-vitro, Cerebellar cells, neutrophils and PC12 cells. Pinealon affected cell survival and growth-related pathways. (source)
• Prenatal stress in rats. animal, Offspring of methionine-loaded pregnant rats. Rat results cannot establish an adult human dose. (source)
• Serotonin in brain-cell cultures. in-vitro, Aging brain cortex cultures and molecular docking. This is the basis of a theoretical serotonergic interaction concern. (source)

Gaps: Human-study count means reports, not proven independent cohorts; locomotive, worker, thesis and older-adult reports may overlap. Reports describe peptide complexes or supplements. Their equivalence to modern synthetic EDR injection vials is unproven. No registered ClinicalTrials.gov study was found under Pinealon. Alternate-name registrations could be missed. The 72-person head-injury report and 75-person emotional-symptom report are summarized in reviews; their primary detailed datasets were not found. The 170-person monograph report may overlap the 2008 paper or thesis. It is not independent replication. A patent describes IM doses of 1 mcg, 10 mcg and 5 mg daily. This is not peer-reviewed confirmation of an injection protocol. No human SC or intranasal dose, dose-ranging trial, drug-level study or validated injection ceiling was verified. No evidence supports a 20 mg oral or injection standard, permanent brain repair, longer life, or predictable telomere benefit. The 32-person abstract has inconsistent sex totals and reports pro-oxidant and CD34+ changes without useful clinical safety follow-up. Rare harms, cancer effects, fertility, pregnancy, breastfeeding and long-term neurological outcomes are unknown. No validated routine laboratory-monitoring schedule or product-specific storage/reconstitution standard was found. Prevalence labels describe this search, not a survey. Only nMentions=1 entries were explicitly counted as individual reports. No Pinealon-specific contamination survey, poison-center case series or US warning letter was located. EU/UK authorization absence and Australian schedule coverage were not fully independently resolved. No published independent clinician dosing guideline was found; the clinical-practice entry is a developer-authored review regimen. Safety blocks and warnings are precautionary screening judgments, not an approved label. Specific risks are identified as theoretical or unstudied.

Related to Pinealon

• Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
• Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
• Thymogen: A Russian peptide used for immune problems, with negative cancer trials.
• Vesugen: An experimental blood-vessel peptide with unclear benefits and poorly defined safety.
• Cortagen: A four-amino-acid brain peptide backed mainly by animal work and unverified patent claims.
• DSIP: An experimental sleep peptide with small, mixed human studies and no FDA-approved dose.

Pinealon: the short version

Sources

• 503B Bulk Drug Substances List, FDA · FDA · 2026
• Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
• Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
• July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), FDA · 2026
• Medicines, European Medicines Agency · European Medicines Agency · 2026
• MHRA Products | Home, MHRA · MHRA · 2026
• Peptide products, Therapeutic Goods Administration · TGA · 2026
• Risks of buying peptide products online, Therapeutic Goods Administration · 2026
• Sepsis, NHS · 2026
• The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
• Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
• Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
• Anaphylaxis, NHS · NHS · 2023
• Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
• Preventing Unsafe Injection Practices, Centers for Disease Control and Prevention

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.